What is a lateral flow device?
The OratectTMMultiple Drug Screen Oral Fluid Testing is based on a competitive immunoassay procedure in which a membrane with immobilized drug derivatives compete with the drug(s) present in oral fluid for limited binding sites on the colored colloidal gold antibody conjugates. During the test, saliva is collected at the collection pad and migrates across the membrane. If no drug is present, the colored colloidal gold conjugates will bind to the drug derivatives on the membrane to form visible bands at specific test regions. If a drug is present, it will bind with the colloidal gold antibody conjugate and prevent the latter from binding with the membrane drug derivative, so no drug band will be formed. The lateral flow is the migration and competition across the membrane.
The Oratect® II Oral Fluid Drug Screen Device is based on a competitive immunoassay procedure in which a membrane with immobilized drug derivatives compete with the drug(s) present in oral fluid for limited binding sites on the colored colloidal gold antibody conjugates. During the test, saliva is collected at the collection pad and migrates across the membrane. If no drug is present, the colored colloidal gold conjugates will bind to the drug derivatives on the membrane to form visible bands at specific test regions. If a drug is present, it will bind with the colloidal gold antibody conjugate and prevent the latter from binding with the membrane drug derivative, so no drug band will be formed. The lateral flow is the migration and competition across the membrane.
Oral Fluid Drug Screen Device is based on a competitive immunoassay procedure in which a membrane with immobilized drug derivatives compete with the drug(s) present in oral fluid for limited binding sites on the colored colloidal gold antibody conjugates. During the test, saliva is collected at the collection pad and migrates across the membrane. If no drug is present, the colored colloidal gold conjugates will bind to the drug derivatives on the membrane to form visible bands at specific test regions. If a drug is present, it will bind with the colloidal gold antibody conjugate and prevent the latter from binding with the membrane drug derivative, so no drug band will be formed. The lateral flow is the migration and competition across the membrane.
